Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719851 | PMC |
| http://dx.doi.org/10.1016/j.jdin.2024.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effective treatment of recalcitrant Hailey-Hailey disease with dupilumab.
JAAD Case Rep
January 2025
Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Recalcitrant Hailey-Hailey disease treated with isotretinoin: A family case series.
JAAD Int
February 2025
Department of Dermatology, College of Medical Sciences, Bharatpur, Nepal.
Long-term remission of Hailey-Hailey disease by Er:YAG ablative laser therapy.
J Eur Acad Dermatol Venereol
October 2024
Department of Dermatology, Centre of Expertise for Genodermatoses, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Background: Hailey-Hailey disease (HHD) is a rare genetic therapy-resistant blistering disease with great disease burden. Treatment is currently focused on symptomatic relief. Er:YAG ablative laser therapy is a therapeutic modality with promising results, though evidence is currently scarce.
View Article and Find Full Text PDFHailey-Hailey Disease Successfully Treated With Adalimumab: A Case Series.
Cureus
August 2024
Dermatology, Ponce Health Sciences University, Ponce, PRI.
Article Synopsis
- - Hailey-Hailey disease is an autosomal dominant condition caused by a mutation in the ATP2C1 gene, leading to painful skin blisters and erosions, particularly in folds of the skin.
- - There is currently no cure for the disease, and treatments mainly focus on managing infections and inflammation, with a recent emphasis on targeting the disease's biochemical pathways.
- - In a case series involving three patients with severe Hailey-Hailey disease, the use of the biologic drug adalimumab successfully controlled their symptoms and maintained remission.
Treatment of Recalcitrant Hailey-Hailey Disease With Naltrexone and Dupilumab: A Report of Two Cases.
Cureus
June 2024
Dermatology, OhioHealth, Columbus, USA.
This report presents two cases of patients with long-standing, treatment-resistant Hailey-Hailey disease (HHD) who experienced significant symptom relief through a combination therapy of oral naltrexone and dupilumab injections. The therapeutic potential of targeting the Th2 pathway and Ca signaling with dupilumab in managing HHD manifestations is highlighted. The findings suggest that Th2 blockade with dupilumab, in conjunction with naltrexone, effectively controls recalcitrant HHD, indicating a role of cytokine response in altering disease pathogenesis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!